NASDAQ:GLYC

GlycoMimetics (GLYC) Stock Forecast, Price & News

$1.50

-0.07 (-4.46%)

(As of 09/29/2023 ET)

Compare

Today's Range: $1.46
▼
$1.57
50-Day Range: $1.29
▼
$1.65
52-Week Range: $0.55
▼
$4.16

Volume: 120,701 shs
Average Volume: 601,876 shs
Market Capitalization: $96.48 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $8.00

GlycoMimetics MarketRank™ Forecast

Analyst Rating: Buy
3.00 Rating Score
Upside/Downside: 433.3% Upside
$8.00 Price Target
Short Interest: Healthy
1.59% of Shares Sold Short
Dividend Strength: N/A
Sustainability: -0.55
Upright™ Environmental Score
News Sentiment: 0.86
Based on 6 Articles This Week
Insider Trading: Acquiring Shares
$48,300 Bought Last Quarter
Proj. Earnings Growth: N/A

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.33 out of 5 stars

Medical Sector

298th out of 973 stocks

Pharmaceutical Preparations Industry

120th out of 450 stocks

3.5

Analyst's Opinion

Consensus Rating
GlycoMimetics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $8.00, GlycoMimetics has a forecasted upside of 433.3% from its current price of $1.50.
Amount of Analyst Coverage
GlycoMimetics has only been the subject of 1 research reports in the past 90 days.

3.0

Short Interest

Percentage of Shares Shorted
1.59% of the outstanding shares of GlycoMimetics have been sold short.
Short Interest Ratio / Days to Cover
GlycoMimetics has a short interest ratio ("days to cover") of 8.8.
Change versus previous month
Short interest in GlycoMimetics has recently decreased by 1.92%, indicating that investor sentiment is improving.

0.0

Dividend Strength

Dividend Yield
GlycoMimetics does not currently pay a dividend.
Dividend Growth
GlycoMimetics does not have a long track record of dividend growth.

4.6

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
GlycoMimetics has received a 73.56% net impact score from Upright. The largest positive contribution comes from its "Creating knowledge" impact, which is false driven by its "Preclinical research services for physical health", "Clinical research services for physical health", and "Basic medical research services" products. See details.
Environmental Sustainability
The Environmental Impact score for GlycoMimetics is -0.55.

2.7

News and Social Media Coverage

News Sentiment
GlycoMimetics has a news sentiment score of 0.86. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.67 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 6 news articles for GlycoMimetics this week, compared to 1 article on an average week.
Search Interest
Only 2 people have searched for GLYC on MarketBeat in the last 30 days. This is a decrease of -60% compared to the previous 30 days.

2.5

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, GlycoMimetics insiders have bought more of their company's stock than they have sold. Specifically, they have bought $48,300.00 in company stock and sold $0.00 in company stock.
Percentage Held by Insiders
Only 8.00% of the stock of GlycoMimetics is held by insiders.
Percentage Held by Institutions
55.36% of the stock of GlycoMimetics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

0.0

Earnings and Valuation

Earnings Growth
Earnings for GlycoMimetics are expected to remain at ($0.61) per share in the coming year.
Price to Earnings Ratio vs. the Market
The P/E ratio of GlycoMimetics is -2.31, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of GlycoMimetics is -2.31, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
GlycoMimetics has a P/B Ratio of 1.83. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About GlycoMimetics (NASDAQ:GLYC) Stock

GlycoMimetics, Inc., a clinical-stage biotechnology company, focuses on the discovery and development of glycobiology-based therapies for cancers, including acute myeloid leukemia (AML) and inflammatory diseases with unmet needs in the United States. It is developing uproleselan, an E-selectin antagonist, which is used in combination with chemotherapy to treat AML, as well as in phase 3 trial to treat relapsed/refractory AML. The company also develops various other programs, including GMI-1687, an antagonist of E-selectin to treat vaso-occlusive crisis; and galectin-3 antagonists, a carbohydrate-binding protein. In addition, it is developing GMI-1359, which targets e-selectin and a chemokine receptor for the treatment of cancers that affect the bone and bone marrow, including solid tumors. The company has a cooperative research and development agreement with the National Cancer Institute; and a collaboration and license agreement with Apollomics (Hong Kong) Limited for the development and commercialization of uproleselan and GMI-1687. GlycoMimetics, Inc. was incorporated in 2003 and is headquartered in Rockville, Maryland.

GLYC Price History

30 days | 90 days | 365 days | Advanced Chart

GLYC Stock News Headlines

September 26, 2023 | benzinga.com

Chief Medical Officer of GlycoMimetics Makes $90K Buy

September 26, 2023 | marketwatch.com

GlycoMimetics Shares Rise 12% After Medical Chief Buys Shares

September 29, 2023 | Oxford Club (Ad)

Better Than Oil Stocks

The best way to profit from energy is NOT a stock...Rather, it's this little-known alternative investment.

September 26, 2023 | finance.yahoo.com

GlycoMimetics Insiders Placed Bullish Bets Worth US$890k

September 26, 2023 | americanbankingnews.com

GlycoMimetics, Inc. (NASDAQ:GLYC) Insider Edwin Rock Acquires 35,000 Shares of Stock

September 6, 2023 | finance.yahoo.com

GlycoMimetics Announces First Cohort Dosed in Human Phase 1a Study of GMI-1687

September 5, 2023 | finance.yahoo.com

GlycoMimetics to Participate in Upcoming H.C. Wainwright 25th Annual Global Investment Conference

August 14, 2023 | msn.com

GlycoMimetics: Q2 2024 Data Readout Makes This Worth A Look, But Cash Is A Problem

September 29, 2023 | Tradewins (Ad)

The Safest Option in Trades!

If you’re new to trading, then you’ve probably heard the wrong thing about options—that they’re risky, unpredictable, or difficult. And it couldn’t be more wrong! With the Hughes Optioneering Strategy, you’ll soon learn that the safest option for new accounts is options themselves!

August 3, 2023 | markets.businessinsider.com

H.C. Wainwright Reaffirms Their Buy Rating on GlycoMimetics (GLYC)

August 2, 2023 | washingtonpost.com

GlycoMimetics: Q2 Earnings Snapshot

August 2, 2023 | msn.com

GlycoMimetics Non-GAAP EPS of -$0.13 beats by $0.04

August 2, 2023 | finance.yahoo.com

GlycoMimetics Reports Highlights and Financial Results for Second Quarter 2023

August 1, 2023 | msn.com

Forte Biosciences closes $25M financing, to advance FB-102 in 2024

August 1, 2023 | markets.businessinsider.com

GlycoMimetics earnings preview: what Wall Street is expecting

July 19, 2023 | finance.yahoo.com

GlycoMimetics to Report Second Quarter 2023 Financial Results on August 2, 2023

June 26, 2023 | seekingalpha.com

GlycoMimetics joins Russell Microcap index

June 26, 2023 | finance.yahoo.com

GlycoMimetics Announces Its Addition to the Russell Microcap® Index

June 15, 2023 | markets.businessinsider.com

H.C. Wainwright Keeps Their Buy Rating on GlycoMimetics (GLYC)

June 15, 2023 | finance.yahoo.com

GlycoMimetics Announces U.S. Food and Drug Administration Clears Addition of Time-based Final Analysis to Pivotal Phase 3 Study of Uproleselan in Relapsed/Refractory Acute Myeloid Leukemia

June 12, 2023 | finance.yahoo.com

We Think GlycoMimetics (NASDAQ:GLYC) Needs To Drive Business Growth Carefully

May 31, 2023 | finance.yahoo.com

GlycoMimetics to Participate in Upcoming Jefferies 2023 Healthcare Conference

May 30, 2023 | msn.com

GlycoMimetics: Insider Buying Continues, And Chart Looks Healthy

May 16, 2023 | finance.yahoo.com

retail investors who own 36% along with institutions invested in GlycoMimetics, Inc. (NASDAQ:GLYC) saw increase in their holdings value last week

May 12, 2023 | seekingalpha.com

GlycoMimetics: An Asymmetric Opportunity That Could Change Hematology

May 4, 2023 | finance.yahoo.com

Q1 2023 GlycoMimetics Inc Earnings Call

May 3, 2023 | finance.yahoo.com

GlycoMimetics Reports Highlights and Financial Results for First Quarter 2023

See More Headlines

Receive GLYC Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for GlycoMimetics and its competitors with MarketBeat's FREE daily newsletter.

GLYC Company Calendar

Last Earnings: 8/02/2023
Today: 9/29/2023
Next Earnings (Estimated): 11/08/2023
Fiscal Year End: 12/31/2023

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Sector: Medical
Current Symbol: NASDAQ:GLYC
CUSIP: N/A
CIK: 1253689
Web: www.glycomimetics.com
Phone: (240) 243-1201
Fax: 301-738-2137
Employees: 38
Year Founded: N/A

Price Target and Rating

Average Stock Price Forecast: $8.00
High Stock Price Forecast: $8.00
Low Stock Price Forecast: $8.00
Forecasted Upside/Downside: +433.3%
Consensus Rating: Buy
Rating Score (0-4): 3.00
Research Coverage: 1 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($0.65)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-46,690,000.00
Net Margins: N/A
Pretax Margin: -56,526.67%
Return on Equity: -71.89%
Return on Assets: -62.70%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 9.19
Quick Ratio: 9.19

Sales & Book Value

Annual Sales: $80,000.00
Price / Sales: 1,206.00
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $0.82 per share
Price / Book: 1.83

Miscellaneous

Outstanding Shares: 64,320,000
Free Float: 59,171,000
Market Cap: $96.48 million
Optionable: Optionable
Beta: 2.05

A Guide To High-Short-Interest Stocks

MarketBeat's analysts have just released their top five short plays for October 2023. Learn which stocks have the most short interest and how to trade them. Click the link below to see which companies made the list.

Get This Free Report

Key Executives

Mr. Harout Semerjian (Age 53)
CEO, Pres & Director
Comp: $1.1M

Ms. Rachel K. King (Age 64)
Co-Founder & Director
Comp: $226.43k

Mr. Brian M. Hahn (Age 49)
Sr. VP & CFO
Comp: $748.27k

Ms. Stephanie R. Irish CPA (Age 52)
VP of Accounting

Mr. Christian B. Dinneen-Long
Gen. Counsel & Company Sec.

Mr. Bruce Johnson (Age 55)
Sr. VP & Chief Commercial Officer

Dr. Edwin Rock M.D. (Age 62)
Ph.D., Sr. VP & Chief Medical Officer

Mr. Chinmaya Rath (Age 47)
Sr. VP & Chief Bus. Officer

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

GLYC Stock - Frequently Asked Questions

Should I buy or sell GlycoMimetics stock right now?: 1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for GlycoMimetics in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "buy" GLYC shares.
View GLYC analyst ratings or view top-rated stocks.
What is GlycoMimetics' stock price forecast for 2023?: 1 analysts have issued 12-month price targets for GlycoMimetics' shares. Their GLYC share price forecasts range from $8.00 to $8.00. On average, they expect the company's share price to reach $8.00 in the next year. This suggests a possible upside of 433.3% from the stock's current price.
View analysts price targets for GLYC or view top-rated stocks among Wall Street analysts.
How have GLYC shares performed in 2023?: GlycoMimetics' stock was trading at $3.03 on January 1st, 2023. Since then, GLYC shares have decreased by 50.5% and is now trading at $1.50.
View the best growth stocks for 2023 here.
When is GlycoMimetics' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Wednesday, November 8th 2023.
View our GLYC earnings forecast.
How were GlycoMimetics' earnings last quarter?: GlycoMimetics, Inc. (NASDAQ:GLYC) posted its quarterly earnings data on Wednesday, August, 2nd. The biotechnology company reported ($0.13) earnings per share for the quarter, beating the consensus estimate of ($0.18) by $0.05.

What other stocks do shareholders of GlycoMimetics own?: Based on aggregate information from My MarketBeat watchlists, some companies that other GlycoMimetics investors own include Exelixis (EXEL), TG Therapeutics (TGTX), Viking Therapeutics (VKTX), Cidara Therapeutics (cdtx), Celldex Therapeutics (CLDX), Dynavax Technologies (DVAX), Spectrum Pharmaceuticals (SPPI), Coherus BioSciences (CHRS), Verastem (VSTM) and Aldeyra Therapeutics (ALDX).
What is GlycoMimetics' stock symbol?: GlycoMimetics trades on the NASDAQ under the ticker symbol "GLYC."
How do I buy shares of GlycoMimetics?: Shares of GLYC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.
What is GlycoMimetics' stock price today?: One share of GLYC stock can currently be purchased for approximately $1.50.
How much money does GlycoMimetics make?: GlycoMimetics (NASDAQ:GLYC) has a market capitalization of $96.48 million and generates $80,000.00 in revenue each year. The biotechnology company earns $-46,690,000.00 in net income (profit) each year or ($0.65) on an earnings per share basis.
How can I contact GlycoMimetics?: GlycoMimetics' mailing address is 9708 MEDICAL CENTER DRIVE, ROCKVILLE MD, 20850. The official website for the company is www.glycomimetics.com. The biotechnology company can be reached via phone at (240) 243-1201, via email at sannes@annesassociates.com, or via fax at 301-738-2137.

This page (NASDAQ:GLYC) was last updated on 9/29/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial